Early Detection of Concealed Cardiac Amyloidosis Using AI-ECG and CT-Derived Extracellular Volume in Patients With Atrial Fibrillation (SEARCH-AF)
This study investigates the clinical efficacy of a non-invasive screening protocol using AI-ECG and CT-ECV analysis for cardiac amyloidosis. The study targets on atrial fibrillation(AF) patients with "red-flag" indicators.
Participants are randomized 1:1 into either an early screening or usual care group.
- Early screening group : AI- ECG and/or CT-ECV analysis + AF treatment
- Usual care group : AF treatment Both groups followed for 2 years to compare CA detection rates and clinical outcomes.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This study is a prospective randomized trial designed to evaluate the clinical utility of non-invasive early screening for cardiac amyloidosis (CA) using AI-ECG and CT-ECV in patients with atrial fibrillation (AF). The study primarily targets patients presenting with "red-flag" signs, such as heart failure symptoms, ECG findings of low voltage or pseudo-infarction, Troponin T > 0.03 ng/L, NT-proBNP > 332 pg/mL, LV wall thickness > 12 mm, a history of carpal tunnel syndrome or spinal canal stenosis, or proteinuria (e.g., UACR ≥ 300 mg/g, 24-hour proteinuria ≥ 0.5-1.0 g/day, or nephrotic-range proteinuria > 3.5 g/day).
The objective is to assess whether early screening improves the detection rate of CA and whether such early detection and subsequent treatment can improve clinical outcomes for patients. Subjects who meet the inclusion and exclusion criteria and provide informed consent will be randomly assigned to either the Early Screening Group or the Usual Care Group in a 1:1 ratio for comparative analysis. Participants will be allocated using stratified block randomization (allocation ratio 1:1) with a computer-generated random number sequence. Stratification variables, including age (age ≥ 75 vs. < 75 years) and sex.
Upon enrollment, all patients will undergo a baseline evaluation encompassing demographic information, medical history, and medication status, along with blood tests (e.g., NT-proBNP, troponin, creatinine). Additionally, AI-ECG analysis using standard 12-lead ECG or ECV analysis using cardiac CT will be performed. For AI-ECG analysis, the Mayo Clinic AI-ECG algorithm will be utilized; raw ECG data will be transmitted, and results will be received only for those patients who have provided specific consent. Patients who test positive in the AI-ECG analysis or cardiac CT-ECV analysis will undergo further diagnostic workup, including SPEP, UPEP, IFE, Free Light Chain Assay, and 99mTc-DPD scintigraphy. For those who test positive in these subsequent evaluations, definitive diagnosis will be attempted through endomyocardial biopsy or genetic testing.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Ju Youn Kim, Ph.D
- Telefonnummer: 82+ 10-5482-7307
- E-post: kzzoo921@gmail.com
Studiesteder
-
-
Seoul
-
Seoul, Seoul, Sør -Korea, 06351
- Samsung Medical Center
-
Ta kontakt med:
- Ju Youn Kim, Ph.D
- Telefonnummer: 82+ 2-3410-3419
- E-post: kzzoo921@gmail.com
-
Ta kontakt med:
- Ju hee Lee, RN
- Telefonnummer: 82+ 2-2148-7611
- E-post: phacyde12@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Adults aged 19 or older who have provided voluntary written informed consent.
- Patients with a history of AF (paroxysmal or persistent) and one or more red-flag symptoms/signs.
- Patients who can undergo at least one of the following: AI-ECG analysis or CT-ECV analysis.
Exclusion Criteria:
- Patients previously diagnosed with cardiac amyloidosis (AL or ATTR).
- Patients with severe heart failure (NYHA class IV) or terminal illness with a life expectancy of less than 1 year.
- Patients deemed inappropriate for participation by the investigator.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Screening
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Early screening group
AI-ECG and/or CT ECV analysis with standard atrial fibrillation treatment
|
Artificial Intelligence-enhanced Electrocardiogram (AI-ECG), developed by Mayo Clinic, is gaining attention as a non-invasive screening tool.
AI-ECG predicts myocardial amyloid deposition based on a standard 12-lead ECG with high accuracy, AUC 0.84(95% CI 0.82-0.86)
In particular, it demonstrated superior performance with an AUC of 0.9 or higher in ECGs exhibiting low voltage or pseudo-infarction patterns, suggesting its potential to detect the disease even before structural changes become apparent.
Myocardial Extracellular Volume (CT-ECV) analysis using cardiac CT is a tissue characterization technique that can be easily added to conventional cardiac CT protocols, enabling the quantification of myocardial fibrosis or infiltrative diseases.
Among 874 subjects who underwent coronary CT, 12.4% exhibited a CT-ECV of ≥ 35%, and cardiac amyloidosis was incidentally discovered in 14.3% of these individuals.
Standard care and treatment in accordance with established AF guidelines.
|
|
Aktiv komparator: Usual care group
Standard atrial fibrillation treatment
|
Standard care and treatment in accordance with established AF guidelines.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Cardiac amyloidosis(CA) detection rate
Tidsramme: From enrollment to the 2 year follow-up
|
CA detection rate in the early screening group based on AI-ECG and CT-ECV results The superiority hypothesis (detection rate of the early screening group > control group) will be tested, utilizing the chi-squared test or Fisher's exact test as the primary analysis.
Effect sizes will be reported as the difference in proportions, odds ratio (OR), and relative risk (RR), along with 95% CIs and p-values.
|
From enrollment to the 2 year follow-up
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Diagnostic Sensitivity and Specificity of AI-ECG alone, CT-ECV alone, and the combined Model
Tidsramme: From enrollment to 2 year follow-up
|
Compare the diagnostic sensitivity and specificity of each model, the difference in proportions between groups will be analyzed as a primary analysis using the chi-squared test or Fisher's exact test.
Furthermore, since the sensitivity and specificity of the AI-ECG, CT-ECV, and combined models are paired indicators derived from the same subjects, the McNemar test will be used for the comparison of sensitivity and specificity between models.
In cases where it is necessary to adjust for covariates (e.g., age, sex, NT-proBNP) or to consider repeated measures/correlation structures, a logistic regression analysis based on Generalized Estimating Equations (GEE) with subject IDs as clusters will be performed to compare model effects.
|
From enrollment to 2 year follow-up
|
|
Correlation of AI-ECG/CT-ECV values with other screening results in patients with confirmed CA
Tidsramme: From enrollment to 2 year follow-up
|
In patients with a confirmed CA, the association between AI-ECG scores/probabilities, CT-ECV (continuous), and clinical findings-such as biopsy results (if available), degree of DPD uptake (e.g., grade), and SPEP/UPEP/IFE results (positive/negative or quantitative values)-will be evaluated using Spearman correlation analysis and, if necessary, logistic or linear regression analysis.
|
From enrollment to 2 year follow-up
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021 Apr 21;42(16):1554-1568. doi: 10.1093/eurheartj/ehab072.
- Oguni T, Takashio S, Kuyama N, Hirakawa K, Hanatani S, Oike F, Usuku H, Matsuzawa Y, Kidoh M, Oda S, Yamamoto E, Ueda M, Hirai T, Tsujita K. Clinical characteristics of patients with high extracellular volume fraction evaluated by cardiac computed tomography for coronary artery evaluation. Eur Heart J Open. 2024 Apr 27;4(3):oeae036. doi: 10.1093/ehjopen/oeae036. eCollection 2024 May.
- Shinzato K, Takahashi Y, Yamaguchi T, Otsubo T, Nakashima K, Yoshioka G, Yokoi K, Tsuruta K, Osako R, Shichida S, Nishimura Y, Edayoshi M, Kawano Y, Shintani-Domoto Y, Miyazaki K, Fukui A, Kawaguchi A, Aoki S, Nomura S, Takahashi N, Ito K, Node K. Atrial amyloidosis identified by biopsy in atrial fibrillation: prevalence and clinical presentation. Eur Heart J. 2025 Sep 15;46(35):3437-3449. doi: 10.1093/eurheartj/ehaf332.
- Yamasaki H, Kondo H, Shiroo T, Iwata N, Masuda T, Makita T, Iwabuchi Y, Tanazawa K, Takahashi M, Ono Y, Ogawa N, Harada T, Mitarai K, Yamauchi S, Takano M, Kodama N, Hirota K, Miyoshi M, Yonezu K, Tawara K, Abe I, Saito S, Fukui A, Fukuda T, Akioka H, Shinohara T, Akiyoshi K, Teshima Y, Yufu K, Daa T, Matsubara E, Asayama Y, Ueda M, Takahashi N. Efficacy of Computed Tomography-Based Evaluation of Myocardial Extracellular Volume Combined With Red Flags for Early Screening of Concealed Cardiac Amyloidosis in Patients With Atrial Fibrillation. Circ J. 2024 Jun 25;88(7):1167-1175. doi: 10.1253/circj.CJ-23-0948. Epub 2024 Mar 22.
- Harmon DM, Mangold K, Suarez AB, Scott CG, Murphree DH, Malik A, Attia ZI, Lopez-Jimenez F, Friedman PA, Dispenzieri A, Grogan M. Postdevelopment Performance and Validation of the Artificial Intelligence-Enhanced Electrocardiogram for Detection of Cardiac Amyloidosis. JACC Adv. 2023 Oct;2(8):100612. doi: 10.1016/j.jacadv.2023.100612. Epub 2023 Sep 14.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i nervesystemet
- Kardiovaskulære sykdommer
- Patologiske prosesser
- Hjertesykdommer
- Nevromuskulære sykdommer
- Metabolisme, medfødte feil
- Genetiske sykdommer, medfødte
- Metabolske sykdommer
- Sykdommer i det perifere nervesystemet
- Arytmier, hjerte
- Nevrodegenerative sykdommer
- Heredodegenerative lidelser, nervesystemet
- Proteostase mangler
- Amyloide nevropatier
- Amyloidose, familiær
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Patologiske tilstander, tegn og symptomer
- Ernæringsmessige og metabolske sykdommer
- Atrieflimmer
- Amyloidose
- Amyloide neuropatier, familiær
Andre studie-ID-numre
- SMC 2025-12-132
- KCT0009027 (Annen identifikator: Korea National Institute of Health)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .